AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AGENUS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.18+0.14 (+2.32%)
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
AGENUS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalties [Member] | $108.59M | $100.98M | $114.57M | $45.29M | $44.36M | – | – | – | – | – | 95.1% | +7.5% |
| Non-Cash Revenue Related to the Sale of Future Royalties [Member] | $108.59M | $100.98M | $114.57M | – | – | – | – | – | – | – | 95.1% | +7.5% |
| Pre-Commercial Product Revenue [Member] | $4.24M | $0 | $0 | – | – | – | – | – | – | – | 3.7% | – |
| Other [Member] | $1.04M | $2.00M | $2.98M | $10.51M | $6.70M | $4.62M | – | – | – | – | 0.9% | -48.3% |
| Service Revenue [Member] | $1.04M | $2.00M | $2.98M | $10.51M | $6.70M | $4.62M | – | – | – | – | 0.9% | -48.3% |
| Research and Development Revenue [Member] | $334.00K | $482.00K | $38.76M | $16.98M | $244.42M | $35.92M | $99.85M | $19.48M | $42.71M | $22.39M | 0.3% | -30.7% |
| Clinical product revenue [Member] | $334.00K | $482.00K | $116.00K | $762.00K | $587.00K | – | – | – | – | – | 0.3% | -30.7% |
| Research and development services [Member] | – | – | $1.44M | $1.68M | $1.48M | $754.00K | $1.71M | $4.15M | $14.62M | $16.87M | – | – |
| License Fee And Milestones Revenue [Member] | – | – | – | – | $220.00M | $22.86M | $75.50M | $14.00M | $24.99M | $2.00M | – | – |
| Recognition of deferred revenue [Member] | – | – | – | – | – | – | – | $1.33M | $3.10M | $3.52M | – | – |
| Other Revenue [Member] | – | – | – | – | $184.00K | $91.00K | $4.68M | – | $168.00K | $179.86K | – | – |
| Recognition of Deferred Grant Revenue [Member] | – | – | – | – | $184.00K | $91.00K | $1.34M | – | $168.00K | $39.00K | – | – |
| Service revenue [Member] | – | – | – | – | – | – | – | – | – | $147.00K | – | – |
| Recognition of deferred research and development revenue [Member] | – | – | $12.21M | $9.54M | $22.36M | $12.30M | $22.64M | $1.33M | $3.10M | – | – | – |
| Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member] | – | $100.98M | $114.57M | $45.29M | $44.36M | $47.55M | $30.42M | $17.31M | – | – | – | – |
| License and Collaboration Revenue [Member] | – | – | – | – | – | – | – | $23.00M | – | – | – | – |
| Non-Cash Royalty Revenue Related to the Sale of Future Royalties and Milestones [Member] | – | – | – | $45.29M | $44.36M | $47.55M | $30.42M | $17.31M | – | – | – | – |
| Upfront License Fee [Member] | – | – | – | – | – | – | $75.50M | – | – | – | – | – |
| Manufacturing services [Member] | – | – | – | – | – | – | $3.34M | – | – | – | – | – |
| Royalty Sales Milestone [Member] | – | – | – | $25.25M | – | – | $15.10M | – | – | – | – | – |
| License fees and milestones [Member] | – | – | $25.00M | $5.00M | $220.00M | $22.86M | – | – | – | – | – | – |
| Clinical product revenue [Member] | – | – | – | – | $587.00K | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $113.16M | $101.46M | $153.34M | $87.51M | $288.96M | $83.55M | $149.36M | $32.78M | $38.88M | $20.33M | 99.1% | +11.5% |
| Rest of World [Member] | $1.04M | $2.00M | $2.98M | $10.51M | $6.70M | $4.62M | $690.00K | $4.00M | – | – | 0.9% | -48.3% |
| Europe [Member] | – | – | – | – | – | – | $690.00K | $4.00M | $3.99M | $2.24M | – | – |
| Rest of World [Member] | – | $2.00M | $2.98M | $10.51M | $6.70M | $4.62M | $690.00K | $4.00M | – | – | – | – |
From the segment and revenue-disaggregation notes of Agenus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.